RAC1 and melanoma: Although this approach is inherently “noisy” due to the significant genetic heterogeneity across human melanoma cell lines, we were nonetheless able to detect a statistically significant sensitivity of RAC1P29S cell lines to the SRF/MRTF inhibitor CCG-1423, and to the RAC1 activation inhibitor EHT-1864 (Figure 4H).